Cuorips Inc. Logo

Cuorips Inc.

Develops iPS cell therapies, like a cardiomyocyte sheet for severe heart failure.

4894 | T

Overview

Corporate Details

ISIN(s):
JP3266030000
LEI:
Country:
Japan
Address:
中央区日本橋本町三丁目11番5号 日本橋ライフサイエンスビルディング2、507
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cuorips Inc. is a regenerative medicine company engaged in the research, development, manufacturing, and commercialization of cell-based therapeutic products. The company specializes in advanced technologies involving induced pluripotent stem (iPS) cells. Its flagship development is the world's first iPS cell-derived cardiomyocyte sheet, a novel treatment targeting severe heart failure. In addition to its own product pipeline, Cuorips is involved in optimizing manufacturing and quality processes and offers contract development services to contribute to the broader advancement of medicine.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 08:13
Registration Form
確認書
Japanese 8.1 KB
2025-11-13 08:07
Interim Report
半期報告書-第10期(2025/04/01-2026/03/31)
Japanese 199.3 KB
2025-06-25 08:39
Post-Annual General Meeting Information
臨時報告書
Japanese 22.9 KB
2025-06-20 08:39
Registration Form
確認書
Japanese 8.1 KB
2025-06-20 08:38
Governance Information
内部統制報告書-第9期(2024/04/01-2025/03/31)
Japanese 21.5 KB
2025-06-20 08:37
Annual Report
有価証券報告書-第9期(2024/04/01-2025/03/31)
Japanese 2.3 MB
2024-11-14 02:30
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-11-14 02:24
Interim Report
半期報告書-第9期(2024/04/01-2025/03/31)
Japanese 162.2 KB
2024-07-01 02:38
Post-Annual General Meeting Information
臨時報告書
Japanese 22.2 KB
2024-06-27 09:38
Governance Information
内部統制報告書-第8期(2023/04/01-2024/03/31)
Japanese 21.2 KB
2024-06-27 09:37
Registration Form
確認書
Japanese 8.1 KB
2024-06-27 09:36
Annual Report
有価証券報告書-第8期(2023/04/01-2024/03/31)
Japanese 2.9 MB
2024-02-13 07:36
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-02-13 07:36
Quarterly Report
四半期報告書-第8期第3四半期(2023/10/01-2023/12/31)
Japanese 132.3 KB
2023-11-10 08:29
Report Publication Announcement
確認書
Japanese 8.2 KB

Automate Your Workflow. Get a real-time feed of all Cuorips Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cuorips Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cuorips Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

co.don AG Logo
Develops personalized cartilage cell transplants for minimally invasive joint repair.
Germany
CNW
Coeptis Therapeutics Holdings, Inc. Logo
Develops cell therapy platforms for cancer, autoimmune, and infectious diseases.
United States of America
COEP
COGNITION THERAPEUTICS INC Logo
Clinical-stage biopharma developing small-molecule drugs for Alzheimer's and dementia.
United States of America
CGTX
Coherus Oncology, Inc. Logo
Commercial-stage biopharma developing immuno-oncology therapies for hard-to-treat cancers.
United States of America
CHRS
COLLEGIUM PHARMACEUTICAL, INC Logo
Develops and commercializes abuse-deterrent medications for responsible chronic pain management.
United States of America
COLL
CollPlant Biotechnologies Ltd Logo
Develops rhCollagen for 3D bioprinting of tissues for regenerative & aesthetic medicine.
United States of America
CLGN
Compass Therapeutics, Inc. Logo
A clinical-stage oncology firm developing antibody therapies that engage the immune system.
United States of America
CMPX
Compugen Ltd. Logo
Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.
Israel
CGEN
COMPUGEN LTD Logo
AI-driven discovery of novel cancer immunotherapies for treatment-resistant patients.
United States of America
CGEN
Connect Biopharma Holdings Ltd Logo
Develops immune modulators for T cell-driven inflammatory diseases like asthma and COPD.
United States of America
CNTB

Talk to a Data Expert

Have a question? We'll get back to you promptly.